Education, Science, Technology, Innovation and Life
Open Access
Sign In
  1. Home
  2. Journals
  3. MEDS Clinical Medicine
  4. Vol 4, Issue 3, 2023

Analysis of the Clinical Effect of Teriparatide and Zoledronic Acid in Postmenopausal Osteoporosis

Download as PDF

DOI: 10.23977/medsc.2023.040316 | Downloads: 7 | Views: 398

Author(s)

Panxiang Li 1, Lan Yang 1, Shike Wu 1, Xiaoming Wu 1, Yilei Liu 1, Meng Cao 2

Affiliation(s)

1 Bone Three Families, Affiliated Hospital of Hebei University, Baoding, Hebei, 071000, China
2 Science and Education, Baoding No.1 Central Hospital, Baoding, Hebei, 071000, China

Corresponding Author

Lan Yang

ABSTRACT

This paper mainly analyzes the clinical effect of teriparatide and zoledronic acid treatment in postmenopausal patients with osteoporosis.56 postmenopausal osteoporosis patients admitted to our hospital were divided into two groups according to the lottery method. 28 patients treated with teriparatide were included in the observation group, and patients treated with zoledronic acid were included in the control group. The study was conducted from January 2021 to September 2022, and the efficacy of the two groups was analyzed and compared.result display, There was no difference between lumbar spine 1-4 and femoral neck BMD, PINP, ALP,β-CTX level, VAS score, BMD level of femoral neck and the probability of adverse drug reactions (P> 0.05); Both groups differ significantly between lumbar 1-4 BMD, femoral neck BMD, PINP, ALP, β -CTX levels, and VAS scores before and after treatment, PINP, ALP, β -CTX levels were higher than before treatment, The control group was lower than before the treatment (P <0.05); The 1-4 BMD levels, PINP, ALP, and β -CTX levels in the treatment observation group were higher than those in the control group (P <0.05); VAS scores at 3 months, 6 months and 1 year compared with the control group (P <0.05). Thus, it is known that teriparatide and zoledronic acid have good therapeutic effects on postmenopausal osteoporosis, which can improve the bone density level of patients, adjust the bone turnover index level, and the medication is relatively safe, but teriparatide is more effective in improving lumbar bone density and reducing pain.

KEYWORDS

Teriparatide; zoledronic acid; postmenopausal osteoporosis; bone mineral density; adverse reactions

CITE THIS PAPER

Panxiang Li, Lan Yang, Shike Wu, Xiaoming Wu, Yilei Liu, Meng Cao, Analysis of the Clinical Effect of Teriparatide and Zoledronic Acid in Postmenopausal Osteoporosis. MEDS Clinical Medicine (2023) Vol. 4: 121-125. DOI: http://dx.doi.org/10.23977/medsc.2023.040316.

REFERENCES

[1] Huguang, Liu Zihan, Li Can, et al. Reticular Meta-analysis of the effectiveness and safety of anti-osteoporosis drugs for the prevention of postmenopausal osteoporotic fractures [J]. Chinese Journal of Osteoporosis, 2020,26 (11): 1646-1654,1699.
[2] Ji Yichao, Zhang Linlin, Yang Huilin. Comparative study of the efficacy of teriparatide and zoledronic acid in the treatment of postmenopausal osteoporotic vertebral fractures [J]. Chinese Journal of Bone and Joint Surgery, 2021,14 (12): 1011-1015.
[3] Gao Qian, Chen Yunxia, Dai Jia, et al. The improvement effect of teriparatide plus raloxifene on abnormal bone metabolism in postmenopausal osteoporosis [J]. Journal of Difficult Diseases, 2020,19 (3): 257-260,265.
[4] Yang Tongbao. Clinical studies of bone healing capsules combined with zoledronic acid in the treatment of postmenopausal osteoporosis [J]. Modern Medicine and Clinical, 2021, (6): 1236-1240.
[5] Liu Yanxia. Clinical efficacy and safety of salmonid calcitonin alendronate combined with estrogen tablets in the treatment of postmenopausal osteoporosis [J]. Shanxi Medical Journal, 2020,49 (4): 442-444.
[6] Chen Qingxian, Liu Lixia, Chen Qingqing, et al. Exploring the effect of tonifying kidney, invigorating spleen and strengthening bone combined with zoledronic acid on bone metabolism and prognosis in postmenopausal osteoporosis [J]. China Journal of Traditional Chinese Medicine, 2022,40 (2): 112-114.
[7] Ma Junteng, Qu Sing, Fu Wenbo. Effect of zoledronic acid combined with fairy bone bao capsule on bone metabolic indexes and carotid intimal thickness in elderly postmenopausal patients with osteoporosis [J]. Medical Theory and Practice, 2021, 34 (24): 4292-4293.
[8] Liu Yuzhang, Li Yaohua, Duan Yonggang, et al. Effect of teriparatide combined with alendronate on bone mineral density, bone metabolism, and quality of life in postmenopausal osteoporosis [J]. Clinical misdiagnosis and mistreatment, 2021, 34 (9): 35-39.
[9] Sun Yuefei, Wang Feifei, Zhang Chen, et al. Effect of alendronate and zoledronic acid on bone mineral density and serum bone metabolic markers in postmenopausal osteoporosis [J]. Maternal and Child Health in China, 2021,36 (24): 5652-5654.
[10] Cheng Maoyang, Zeng Huadong, Lu Guohua, et al. Comparative analysis of the effects of zoledronic acid and teriparatide on lumbar interbody fusion in patients with osteoporosis [J]. Chinese Journal of Bone and Joint Surgery, 2022, 15 (3): 176-182.
[11] Li Haiming, Dong Bingzi, Yang Nailong, et al. Clinical comparative study of teriparatide and zoledronic acid in the treatment of postmenopausal low transformation type osteoporosis [J]. Advances in Clinical Medicine, 2021,11 (6): 2670-2677.

Subscription
E-Mail Alert
Most popular papers
Call for Special Issue
Publication Ethics & OA Statement
Plagiarism Policy
Contact Us
Downloads: 4408
Visits: 193761

Sponsors, Associates, and Links

All published work is licensed under a Creative Commons Attribution 4.0 International License.

Copyright © 2016 - 2031 Clausius Scientific Press Inc. All Rights Reserved.